Conferences
Sharing our expertise on current biopharmaceutical topics worldwide
22-24
SEP 2020
Virtual
Workshop by Dr. Steven Chamow: The Process of CDMO Selection for Bispecific Antibody Development: Matching Capabilities to Need
21-25
SEP 2020
Virtual
Presentation by Dr. Steven Chamow: Capture of CH1-Containing Bispecific Antibodies: An Alternative to Protein A
9-10
OCT 2018
BioProduction Congress 2018
Dublin, Ireland
Presentation by Dr. Steven Chamow: An Alternative to Protein A for capture of Fc-containing bispecific antibodies
8-12
JAN 2018
17th Annual CHI PepTalk Conference
San Diego, CA
Presentation by Dr. Steven Chamow: Making Proteins “Druggable”: Fc Fusion Proteins as a Therapeutic Class
11-15
DEC 2016
IBC Antibody Engineering Conference
San Diego, CA
Workshop with Dr. Steven Chamow: The Process of CMO Selection for Antibody Development: Matching Capabilities to Need
28-30
SEP 2015
5th World Conference on Cancer Therapy
Atlanta, GA
19-23
JAN 2015
14th Annual CHI PepTalk Conference
San Diego, CA
Presentation by Dr. Steven Chamow: Molecular engineering of Fc fusion proteins to tailor effector function to clinical indication
13-19
JAN 2014
13th Annual CHI PepTalk Conference
Palm Springs, CA
Speaker: Structural variation among antibody Fc-fusion proteins for human therapy
19-22
AUG 2013
The BioProcessing Summit
Boston, MA
Speaker: Challenges and tradeoffs in developing a scalable mAb process on a constrained budget: A case study
29-2
FEB-MAR 2012
IBC 3rd Annual Recombinant Protein and Complex Biologics Development and Production
San Diego, CA
Speaker: Cellular synthesis of antibody fusion proteins
19
APR 2012
Laureate Pharma Scientific Advisory Board
Princeton, NJ
Presentation by Dr. Steven Chamow: Biosimilars and Biobetters
22
AUG 2011
CHI Bioprocessing Summit
Boston, MA
Presentation by Dr. Steven Chamow: Use of Design of Experiements to Develop a Highly Productive Process for Manufacture of a Chimeric mAb in GS-CHO Cells
15-18
MAY 2011
ESACT 2011
Vienna, Austria
Workshop organizer and chair: Fc Fusion Proteins: A Growing Class of Therapeutics